Bausch Health Companies Inc. Contracts & Agreements

Credit and Security Agreement, dated June 30, 2023, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the... (Filed With SEC on July 7, 2023)

Stock and Asset Purchase Agreement by and among Buyer, Novartis and, for the limited purposes set forth therein, Bausch + Lomb, dated as of June 30, 2023 (Filed With SEC on July 7, 2023)

Form of PSU Award Agreement (Filed With SEC on May 4, 2023)

Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. and the Bank of New York Mellon, as trustee, amending that certain... (Filed With SEC on November 3, 2022)

Fifteenth Supplemental Indenture, dated as of September 28, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain... (Filed With SEC on November 3, 2022)

Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain... (Filed With SEC on November 3, 2022)

Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. (BHA) and the Bank of New York Mellon, as trustee, amending that... (Filed With SEC on November 3, 2022)

Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes... (Filed With SEC on October 4, 2022)

Indenture, dated as of September 30, 2022, by and among 1375209 B.C. Ltd., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, as notes collateral agent (Filed With SEC on October 4, 2022)

Employment Agreement, dated as of October 20, 2021, by and between Bausch Health Companies Inc. and Tom Vadaketh (Filed With SEC on August 9, 2022)

Employment Agreement, dated as of December 3, 2021, by and between Bausch Health Companies Inc. and Seana Carson (Filed With SEC on August 9, 2022)

Employment Agreement, dated as of May 28, 2020, by and between Bausch Health Companies Inc. and Robert Spurr (Filed With SEC on August 9, 2022)

Amendment to Employment Agreement dated September 1, 2021 by and between Bausch Health Companies Inc. and Robert Spurr (Filed With SEC on August 9, 2022)

Separation Agreement, dated as of June 1, 2022, by and between Bausch Health Companies Inc. and Robert Spurr (Filed With SEC on August 9, 2022)

Form of RSU Grant Agreement (Filed With SEC on May 10, 2022)

Form of Option Grant Agreement (Filed With SEC on May 10, 2022)

Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio (Filed With SEC on February 23, 2022)

Form of 2021 Share Unit Grant Agreement (TSR Performance Restricted Share Units) under the Amended and Restated 2014 Omnibus Incentive Plan (Filed With SEC on November 2, 2021)

Amendment to Employment Agreement dated April 28, 2021 between Bausch Health Companies Inc. and Paul Herendeen (Filed With SEC on November 2, 2021)

Employment Agreement, dated as of June 1, 2021, by and between Bausch Health Companies Inc. and Sam Eldessouky (Filed With SEC on August 3, 2021)

Indenture, dated as of June 8, 2021 by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral... (Filed With SEC on June 8, 2021)

Form of 2021 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units) under the Amended and Restated 2014 Omnibus Incentive Plan (Filed With SEC on May 4, 2021)

Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 28, 2020 (the "Amended and Restated 2014 Omnibus Incentive Plan") (Filed With SEC on February 24, 2021)

Form of Spinoff Bonus Program Letter Agreement dated November 2, 2020 (Filed With SEC on February 24, 2021)

Director Nomination and Appointment Agreement by and among Bausch Health Companies Inc., Carl C. Icahn and the persons and entities listed therein, dated February 23, 2021 (Filed With SEC on February 24, 2021)

Indenture, dated as of December 3, 2020, by and among Bausch Health Companies Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee (Filed With SEC on December 3, 2020)

Indenture, dated as of May 26, 2020, by and among Bausch Health Companies Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee (Filed With SEC on May 26, 2020)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended (Filed With SEC on February 19, 2020)

Bausch Health Companies Inc. Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 30, 2018 (the "Amended and Restated 2014 Omnibus Incentive Plan") (Filed With SEC on February 19, 2020)

Stipulation of Settlement dated December 15, 2019 in the U.S. Securities Litigation (Filed With SEC on February 19, 2020)

Indenture, dated as of December 30, 2019, by and among Bausch Health Companies Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee (Filed With SEC on December 30, 2019)

Indenture, dated as of May 23, 2019, by and among Bausch Health Companies Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee (Filed With SEC on May 24, 2019)

Employment Agreement dated August 2, 2018 between Bausch Health Companies Inc. and Joseph F. Gordon (Filed With SEC on May 6, 2019)

Form of 2016 Stock Option Grant Agreement, under the 2014 Omnibus Incentive Plan (Filed With SEC on May 6, 2019)

Amended and Restated Supply Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant Pharmaceuticals Luxembourg s. r.l.... (Filed With SEC on February 20, 2019)

Amendment No. 2 to the Amended and Restated License Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant... (Filed With SEC on February 20, 2019)

Amended and Restated Asset Purchase Agreement dated January 4, 2019 among Bausch Health Companies Inc., Bausch Health Ireland Limited, Synergy Pharmaceuticals Inc. and Synergy... (Filed With SEC on February 20, 2019)

Form of Matching Restricted Stock Unit Agreement (Matching Units) under the Bausch Health Companies Inc. Amended and Restated 2014 Omnibus Incentive Plan (Filed With SEC on August 7, 2018)

Form of Common Share Certificate of Bausch Health Companies Inc (Filed With SEC on July 16, 2018)

Indenture, dated as of June 1, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., the other guarantors party thereto and The... (Filed With SEC on June 1, 2018)

Form of Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of Stock Option Grant Agreement (Nonstatutory Stock Options), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of Restricted Stock Unit Award Agreement (Restricted Stock Units), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of Retention Restricted Stock Unit Award Agreement, under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of Director Restricted Share Units Award Agreement (Annual Grants), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of 2018 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of 2018 Restricted Stock Unit Agreement, under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Form of 2018 Stock Option Grant Agreement (Nonstatutory Stock Options), under the 2014 Omnibus Incentive Plan (Filed With SEC on February 28, 2018)

Employment Agreement between Valeant Pharmaceuticals International, Inc. and William Humphries, dated December 1, 2016 (Filed With SEC on February 28, 2018)

Employment Agreement between Valeant Pharmaceuticals International, Inc. and Thomas Appio, dated March 23, 2017 (Filed With SEC on February 28, 2018)

Indenture, dated as of December 18, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee (Filed With SEC on December 18, 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. FORM OF SHARE UNIT GRANT AGREEMENT (PERFORMANCE VESTING) (PERFORMANCE RESTRICTED SHARE UNITS) (2014 Omnibus Incentive Plan) (Filed With SEC on March 1, 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. FORM OF STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION) (2014 Omnibus Incentive Plan) (Filed With SEC on March 1, 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 2014 OMNIBUS INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AWARDAGREEMENT (RESTRICTED STOCK UNITS) (Filed With SEC on March 1, 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 2014 OMNIBUS INCENTIVE PLAN MAKE-WHOLE AWARD AGREEMENT (RESTRICTED STOCK UNITS) (Filed With SEC on March 1, 2017)

[Signature Page Follows] (Filed With SEC on March 1, 2017)

SEPARATION AGREEMENT (Filed With SEC on March 1, 2017)

[Signature PageFollows] (Filed With SEC on March 1, 2017)

SEPARATION AGREEMENT (Filed With SEC on March 1, 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. EMPLOYMENT AGREEMENT (Filed With SEC on August 23, 2016)

SEPARATION AGREEMENT (Filed With SEC on May 31, 2016)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 2014 OMNIBUS INCENTIVE PLAN MATCHING RESTRICTED STOCK UNIT AWARD AGREEMENT (MATCHING UNITS) (Filed With SEC on April 29, 2016)

Page 2 of 4 (Filed With SEC on April 29, 2016)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. EMPLOYMENT AGREEMENT (Filed With SEC on April 27, 2016)

General Waiver & Release (Filed With SEC on February 2, 2016)

SEPARATION AGREEMENT (Filed With SEC on July 28, 2015)

JOINDER AGREEMENT (Filed With SEC on April 30, 2015)

VRX ESCROW CORP. $2,000,000,000 5.375% SENIOR NOTES DUE 2020 $3,250,000,000 5.875% SENIOR NOTES DUE 2023 1,500,000,000 4.50% SENIOR NOTES DUE 2023 $3,250,000,000 6.125% SENIOR... (Filed With SEC on March 27, 2015)

SUPPLEMENTAL INDENTURE RELATED TOTHE ASSUMPTION (Filed With SEC on March 27, 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. $1,450,000,000 of Common Shares Underwriting Agreement (Filed With SEC on March 18, 2015)

AMENDMENTNO. 1 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on March 16, 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. SHARE UNIT GRANT AGREEMENT (PERFORMANCE VESTING) (PERFORMANCE RESTRICTED SHARE UNITS) (2014 Omnibus Incentive Plan) (Filed With SEC on February 25, 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION) 2014 OMNIBUS INCENTIVE PLAN (Filed With SEC on February 25, 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 2014 OMNIBUS INCENTIVE PLAN MATCHING RESTRICTED STOCK UNIT AWARD AGREEMENT (MATCHING UNITS) (Filed With SEC on February 25, 2015)

SUCCESSOR AGENT AGREEMENT AND AMENDMENT NO. 9 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on February 25, 2015)

JOINDER AGREEMENT (Filed With SEC on February 25, 2015)

AGREEMENT AND PLAN OF MERGER by and among VALEANTPHARMACEUTICALS INTERNATIONAL, SUN MERGER SUB, INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and SALIX PHARMACEUTICALS,LTD.... (Filed With SEC on February 23, 2015)

DEUTSCHE BANK AG NEW YORK BRANCH DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH DEUTSCHE BANK SECURITIES INC. 60 Wall Street New York,NY 10005 (Filed With SEC on February 23, 2015)

VALEANT PHARMACEUTICALSINTERNATIONAL, INC. 5.50% SENIOR NOTES DUE 2023 INDENTURE DATED AS OFJANUARY 30, 2015 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF... (Filed With SEC on January 30, 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT J. MICHAEL PEARSON (Filed With SEC on January 13, 2015)

SEPARATION AGREEMENT (Filed With SEC on May 9, 2014)

Valeant Pharmaceuticals International, Inc. (Filed With SEC on February 28, 2014)

Sincerely, (Filed With SEC on February 28, 2014)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 5.625% SENIOR NOTES DUE 2021 INDENTURE DATED AS OF DECEMBER 2, 2013 THE BANK OFNEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF... (Filed With SEC on December 2, 2013)

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on November 1, 2013)

AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on November 1, 2013)

SECOND SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

THIRD SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SIXTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

EIGHTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

THIRD SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FOURTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

EIGHTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

NINTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FOURTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FIFTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

EIGHTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

NINTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FIFTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SIXTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

NINTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

ELEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SIXTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

ELEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TWELFTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

SEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

EIGHTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

ELEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TWELFTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

THIRTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

EIGHTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

NINTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TWELFTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

THIRTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FOURTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

NINTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

TENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

THIRTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FOURTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

FIFTEENTH SUPPLEMENTAL INDENTURE (Filed With SEC on November 1, 2013)

VPII ESCROW CORP. 6.75% SENIOR NOTES DUE 2018 7.50% SENIOR NOTES DUE 2021 INDENTURE DATED AS OF JULY 12, 2013 THE BANK OFNEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF... (Filed With SEC on July 12, 2013)

SUPPLEMENTAL INDENTURE RELATED TO THE ASSUMPTION (Filed With SEC on July 12, 2013)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. $2,000,000,020 of Common Shares Underwriting Agreement (Filed With SEC on June 24, 2013)

AGREEMENT AND PLAN OF MERGER BY AND AMONG VALEANT PHARMACEUTICALS INTERNATIONAL, VALEANT PHARMACEUTICALS INTERNATIONAL, INC., STRATOS MERGER CORP. and BAUSCH & LOMB HOLDINGS... (Filed With SEC on May 31, 2013)

GOLDMAN SACHS LENDING PARTNERS LLC GOLDMAN SACHS BANK USA 200 West Street New York, New York 10282 (Filed With SEC on May 31, 2013)

SEPARATION AGREEMENT (Filed With SEC on May 14, 2013)

SEVENTH SUPPLEMENTAL INDENTURE (Filed With SEC on May 3, 2013)

SIXTH SUPPLEMENTAL INDENTURE (Filed With SEC on May 3, 2013)

FIFTH SUPPLEMENTAL INDENTURE (Filed With SEC on May 3, 2013)

SECOND SUPPLEMENTAL INDENTURE (Filed With SEC on May 3, 2013)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on May 3, 2013)

ASSET PURCHASE AGREEMENT DATED AS OF NOVEMBER 18, 2011 BY AND BETWEEN MEDICIS PHARMACEUTICAL CORPORATION AND GRACEWAY PHARMACEUTICALS, LLC AND THE OTHER PARTIES SIGNATORY HERETO (Filed With SEC on February 28, 2013)

AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on November 5, 2012)

AMENDMENT NO.2 TO THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on November 5, 2012)

JOINDER AGREEMENT (Filed With SEC on November 5, 2012)

JPMORGAN CHASE BANK, N.A. 270 Park Avenue New York, New York 10017 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10017 (Filed With SEC on November 5, 2012)

SEPARATION AGREEMENT (Filed With SEC on November 5, 2012)

VPI ESCROW CORP. 6.375% SENIOR NOTES DUE 2020 INDENTURE DATED AS OF OCTOBER 4, 2012 THE BANK OFNEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF CONTENTS (Filed With SEC on October 9, 2012)

SUPPLEMENTAL INDENTURE RELATED TO THE ASSUMPTION (Filed With SEC on October 9, 2012)

VALEANT PHARMACEUTICALSINTERNATIONAL 6.375% SENIOR NOTES DUE 2020 INDENTURE DATED AS OF OCTOBER 4, 2012 THE BANK OFNEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF CONTENTS (Filed With SEC on October 9, 2012)

JOINDER AGREEMENT (Filed With SEC on October 9, 2012)

AGREEMENT AND PLAN OF MERGER Among MEDICISPHARMACEUTICAL CORPORATION, VALEANT PHARMACEUTICALS INTERNATIONAL, VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and MERLIN MERGER SUB,... (Filed With SEC on September 4, 2012)

JPMORGAN CHASE BANK, N.A. 270 Park Avenue New York, New York 10017 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10017 (Filed With SEC on September 4, 2012)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

FIFTH SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

FOURTH SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

THIRD SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

SIXTH SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

FIFTH SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

FOURTH SUPPLEMENTAL INDENTURE (Filed With SEC on August 3, 2012)

JOINDER AGREEMENT (Filed With SEC on August 3, 2012)

JOINDER AGREEMENT (Filed With SEC on June 15, 2012)

SECOND SUPPLEMENTAL INDENTURE (Filed With SEC on February 29, 2012)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on February 29, 2012)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION) 2011 OMNIBUS INCENTIVE PLAN (Filed With SEC on February 29, 2012)

VALEANT PHARMACEUTICALS INTERNATIONAL 2011 OMNIBUS INCENTIVE PLAN MATCHING RESTRICTED STOCK UNIT AWARD AGREEMENT (MATCHING UNITS) (Filed With SEC on February 29, 2012)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. SHARE UNIT GRANT AGREEMENT (PERFORMANCE VESTING) (PERFORMANCE RESTRICTED SHARE UNITS) (2011 Omnibus Incentive Plan) (Filed With SEC on February 29, 2012)

AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on February 29, 2012)

SECOND AMENDED AND RESTATED CREDIT AND GUARANTYAGREEMENT dated as of October 20, 2011 among VALEANT PHARMACEUTICALS INTERNATIONAL, INC., as Borrower, CERTAIN SUBSIDIARIES OF... (Filed With SEC on October 26, 2011)

AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT ANDGUARANTY AGREEMENT (Filed With SEC on October 26, 2011)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on October 26, 2011)

SECOND SUPPLEMENTAL INDENTURE (Filed With SEC on October 26, 2011)

THIRD SUPPLEMENTAL INDENTURE (Filed With SEC on October 26, 2011)

AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on August 15, 2011)

AMENDMENT NO. 1 TO CREDIT AND GUARANTY AGREEMENT (Filed With SEC on August 15, 2011)

AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT (Filed With SEC on August 15, 2011)

ASSET PURCHASE AGREEMENT among SANOFI, VALEANT INTERNATIONAL (BARBADOS) SRL and VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Dated July 8, 2011 (Filed With SEC on August 8, 2011)

DATED 29 JUNE 2011 MEDA PHARMA SARL - and - VALEANT INTERNATIONAL (BARBADOS) SRL (Filed With SEC on August 8, 2011)

SEPARATION AGREEMENT (Filed With SEC on July 7, 2011)

$200,000,000 Revolving Credit Facility (Filed With SEC on July 6, 2011)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (Filed With SEC on March 23, 2011)

incur or guarantee additional debt (Filed With SEC on March 10, 2011)

STOCK PURCHASE AGREEMENT between and among Biovail International S..r.l., and the Stockholders of PharmaSwiss SA January 31, 2011 (Filed With SEC on February 28, 2011)

ASSET PURCHASE AGREEMENT by and between BIOVAIL LABORATORIES INTERNATIONAL SRL and GLAXOSMITHKLINE LLC dated as of February 2, 2011 (Filed With SEC on February 28, 2011)

ARTICLE I PURCHASE AND SALE OF THE PURCHASED SECURITIES (Filed With SEC on February 28, 2011)

W I T N E S S E T H : (Filed With SEC on February 28, 2011)

TRADEMARK AND DOMAIN NAME LICENSE AGREEMENT (Filed With SEC on February 28, 2011)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. STOCK OPTION GRANT NOTICE (NONSTATUTORY STOCK OPTION) 2007 EQUITY COMPENSATION PLAN (Filed With SEC on February 28, 2011)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. UNIT GRANT NOTICE (2007 Equity Compensation Plan) (Filed With SEC on February 28, 2011)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. UNIT GRANT NOTICE (PERFORMANCE VESTING) (PERFORMANCE RESTRICTED SHARE UNITS) (2007 Equity Compensation Plan) (Filed With SEC on February 28, 2011)

VALEANT PHARMACEUTICALS INTERNATIONAL (Filed With SEC on February 9, 2011)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Filed With SEC on December 27, 2010)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Filed With SEC on December 14, 2010)

VALEANT PHARMACEUTICALS INTERNATIONAL (Filed With SEC on November 26, 2010)

By: /s/ J. Michael Pearson J. Michael Pearson Chief Executive Officer /s/ Rajiv De Silva Rajiv De Silva (Filed With SEC on November 17, 2010)

Old Valeant funded a one-time special cash dividend of $16.77 per share of Old Valeant Common Stock to Old Valeant stockholders of record as of the close of business on September... (Filed With SEC on October 1, 2010)

CONFIDENTIAL TREATMENT REQUESTED: Portions of this Exhibit have been redacted pursuant to a request forconfidential treatment under Rule 24b-2 of the General Rules and... (Filed With SEC on February 26, 2010)

CONFIDENTIAL TREATMENT REQUESTED: Portions of this Exhibit have been redacted pursuant to a requestfor confidential treatment under Rule 24b-2 of the General Rules andRegulations... (Filed With SEC on February 26, 2010)

AMENDMENT NO .1 TO ASSET PURCHASE AGREEMENT BETWEEN CAMBRIDGE LABORATORIES(IRELAND) LIMITED AND BIOVAIL LABORATORIESINTERNATIONAL (BARBADOS) SRL Dated June 19th, 2009 (Filed With SEC on February 26, 2010)

Category

Industry

Companies

Contracts

Bausch Health Companies Inc. Contracts & Agreements